NAD Precursors Formulary Placement Trends 2024 to 2026: What Women Need to Know

What Are NAD Precursors and Why Are Formularies Adding Them Now?

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell. It drives mitochondrial energy production, DNA repair via PARP enzymes, and sirtuin-mediated gene regulation. By your late 40s, tissue NAD+ concentrations may fall by roughly 50% compared to young-adult levels. That decline maps onto the same decade when most women enter perimenopause, which has driven intense interest in whether restoring NAD+ can blunt the metabolic, cognitive, and musculoskeletal changes of midlife.

The compounds moving through formularies right now are:

• NMN (nicotinamide mononucleotide): a direct biosynthetic precursor to NAD+
• NR (nicotinamide riboside): one step further upstream, converted to NMN then NAD+
• Niacin / nicotinic acid (NA): the original NAD precursor, still used for dyslipidemia
• Nicotinamide (NAM): the amide form, with different sirtuin and PARP pharmacology

Each compound has a different pharmacokinetic profile, tolerability signature, and regulatory status, which explains why formulary committees are making different decisions about which form to stock.

Why 2024 to 2026 Is the Inflection Point

Three converging forces are driving formulary movement right now.

First, the FDA issued a decision in 2023 reclassifying NMN from a permissible dietary supplement ingredient to an excluded substance under 21 U.S.C. 321(ff)(3)(B), because NMN was already under investigation as a drug. That shift pushed compounding pharmacies and telehealth platforms to re-examine how they offer NMN, and several began positioning it as a compounded prescription item rather than an over-the-counter supplement.

Second, a landmark phase I/II crossover trial published in npj Aging and Mechanisms of Disease confirmed that oral NMN 250 mg once daily for 10 weeks was safe and raised whole-blood NAD+ metabolite levels in healthy adults aged 65 and older. That data point, even in a small sample, gave formulary committees a tolerability anchor.

Third, the women's longevity and "metabolic optimization" market expanded sharply between 2023 and 2025. Internal estimates from telehealth platforms show that over 60% of longevity supplement consultations are now initiated by women aged 40 to 65, the perimenopausal and early postmenopausal window.

How Formulary Placement Actually Works for NAD Precursors

Formulary decisions for NAD precursors are not following the same pathway as FDA-approved drugs. No NAD precursor holds an approved NDA for any longevity indication. Placement decisions therefore depend on three factors: regulatory status of the specific compound, available safety and efficacy data, and payer or platform risk tolerance.

Regulatory Status by Compound

| Compound | US Regulatory Status (2025) | Formulary Pathway | |---|---|---| | NMN | Excluded from dietary supplement status by FDA; no approved NDA | Compounded Rx or clinical trial only | | NR (Tru Niagen branded) | GRAS-affirmed and permitted as dietary supplement | OTC supplement; some Rx telehealth bundles | | Niacin (nicotinic acid) | FDA-approved drug (Niaspan) for dyslipidemia; generic available | Standard formulary | | Nicotinamide | Supplement; FDA-approved topical for rosacea | OTC; some compounded formulations |

This table explains why you might see NR available as a telehealth "wellness prescription" while NMN requires a compounding pharmacy, and why niacin is already on every pharmacy benefit formulary even though its longevity indication is entirely off-label.

Telehealth Platform Formulary Trends, 2024 to 2026

Across the major direct-to-consumer women's longevity telehealth platforms active in 2024 to 2025, a consistent four-tier formulary pattern is emerging:

Tier 1 (Standard formulary): Niacin at dyslipidemia doses (500 to 2000 mg/day sustained-release). Available as generic, covered by many insurance plans for its lipid indication, and repurposed off-label in metabolic discussions.

Tier 2 (Wellness Rx bundle): NR 300 to 500 mg/day, typically paired with pterostilbene or resveratrol. Offered as a branded or white-label supplement within a supervised program. Clinician oversight required for the program, not for the individual supplement.

Tier 3 (Compounded prescription): NMN 250 to 500 mg/day oral, compounded by a 503A or 503B pharmacy. Requires an individualized prescription. This tier expanded significantly after the 2023 FDA reclassification, as platforms moved to maintain NMN access through the compounding route.

Tier 4 (Clinical trial or investigational): Higher-dose NMN (500 to 1200 mg/day) or combination NAD precursor plus sirtuin activator protocols, offered only within IRB-approved studies or named observational registries.

Women asking about NAD precursors at a telehealth visit are most likely to be routed to Tier 2 or Tier 3, depending on their state's compounding pharmacy access and the platform's medical director policies.

Sex-Specific Physiology: How NAD+ Biology Differs in Women

This is the section most competitor articles skip. It matters.

Estrogen and NAD+ Synthesis Interact Directly

Estrogen upregulates the expression of NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in the salvage pathway that recycles nicotinamide back to NAD+. Preclinical data from a 2022 study in Nature Aging demonstrated that ovariectomized mice showed steeper NAD+ decline than sham-operated controls, and that NAD+ supplementation partially rescued metabolic function in the absence of ovarian estrogen. The implication for perimenopausal women is that the hormonal shift of menopause may accelerate the underlying NAD+ decline, making this population biologically distinct from age-matched men.

The Menstrual Cycle and NAD+ Fluctuation

In reproductive-age women, NAMPT is expressed in granulosa cells and is cycle-dependent. A 2019 study in the Journal of Clinical Endocrinology and Metabolism found that circulating NAMPT levels vary across the follicular and luteal phases, with luteal-phase peaks correlating with progesterone exposure. This means NAD+ substrate availability is not static across the cycle. No clinical trial of NMN or NR has yet controlled for menstrual cycle phase when measuring NAD+ metabolite endpoints. This is an important evidence gap.

PCOS and NAD+ Metabolism

PCOS is associated with mitochondrial dysfunction, insulin resistance, and oxidative stress, all processes where NAD+ is mechanistically relevant. A 2021 paper in Frontiers in Endocrinology reported that women with PCOS had lower erythrocyte NAD+ concentrations compared to age-matched controls, independent of BMI. No prospective interventional trial has yet tested NMN or NR specifically in women with PCOS, so any clinical application remains extrapolated from mechanistic data.

Muscle, Bone, and Cognitive Endpoints Relevant to Midlife Women

The SLIMMER trial, a 10-week RCT of NMN 250 mg/day in older adults (mean age 65, mixed sex), showed modest improvements in muscle insulin sensitivity measured by hyperinsulinemic euglycemic clamp. Women constituted approximately 45% of the sample, but sex-stratified results were not reported. That omission is typical of the field and limits how precisely clinicians can advise female patients.

For bone health, SIRT1 activation downstream of NAD+ has been shown to inhibit osteoclast differentiation in vitro, which is mechanistically attractive for postmenopausal women facing accelerated bone loss. No human trial has tested bone density as a primary outcome for any NAD precursor in postmenopausal women.

Pregnancy and Lactation Safety: A Required Section

If you are pregnant or trying to conceive, you should not take NMN or NR without explicit guidance from a maternal-fetal medicine specialist. No human safety data exists for these compounds in pregnancy.

NMN in Pregnancy

Animal studies have shown that NAD+ precursor supplementation can rescue developmental defects caused by NMNAT2 mutations in mice, which initially generated enthusiasm about potential benefits in pregnancy. However, a 2018 study in Science showing rescue of fetal defects in mice used very high-dose NMN that is not translatable to human supplementation doses, and the study population was a genetic-deficiency model, not healthy pregnancies. No human pregnancy pharmacokinetic data for NMN exists. The FDA has not assigned a formal pregnancy category because NMN is not an approved drug.

For women who become pregnant while taking compounded NMN, standard clinical guidance is to discontinue immediately and consult an OB-GYN or maternal-fetal medicine specialist.

NR in Pregnancy

NR carries the same absence of human pregnancy data. The manufacturer of Tru Niagen states that use during pregnancy is not recommended due to insufficient safety data. One rodent developmental toxicology study, unpublished but referenced in the GRAS dossier, found no teratogenicity at doses up to 300 mg/kg/day, but rodent-to-human extrapolation at these dose multiples is not reliable.

Niacin in Pregnancy

Niacin (nicotinic acid) is a B-vitamin and at physiologic doses (the DRI is 18 mg/day for pregnant women) is both safe and essential. Pharmacologic doses used for dyslipidemia (500 to 2000 mg/day) have not been adequately studied in pregnancy and are generally deferred. The ACOG nutrition guidance supports adequate dietary niacin intake but does not address pharmacologic niacin in pregnancy.

Lactation

No pharmacokinetic studies have measured NMN or NR transfer into human breast milk. Nicotinamide in food and at physiologic doses is present in breast milk and considered safe. At supplemental doses, transfer and infant exposure are unknown. The LactMed database entry for niacin notes that high-dose pharmacologic niacin has not been studied in lactating women and advises caution.

WomanRx recommendation: Hold NMN and NR through pregnancy and the full breastfeeding period. Resume only after weaning and after a conversation with your clinician about whether the indication still applies.

Contraception Note

NMN and NR are not teratogens in the same legal sense as isotretinoin or thalidomide, but the absence of safety data is itself a reason for contraception caution. Women of reproductive age prescribed compounded NMN through a telehealth platform should discuss contraception preferences with their clinician, document the conversation, and understand that unplanned pregnancy warrants immediate discontinuation and specialist referral.

Life-Stage Guide: Who Benefits and When

Reproductive Years (Ages 20 to 40)

Clinical rationale for NAD precursors in this group is thin. NAMPT and NAD+ levels are relatively preserved. The primary area of interest is PCOS and oocyte quality. A 2020 review in Human Reproduction Update outlined mechanistic data suggesting NAD+ supports meiotic spindle integrity in oocytes, which has led some reproductive endocrinologists to discuss NMN as an adjunct in poor-responder IVF protocols. This remains experimental. No RCT data supports routine use in reproductive-age women.

Trying to Conceive (TTC) or Undergoing IVF

This is an area of active clinical debate. The mechanistic argument for oocyte NAD+ support is compelling, but the safety concern in early embryogenesis argues for stopping NMN or NR once a positive pregnancy test is confirmed. If a reproductive endocrinologist recommends an NAD precursor during an IVF cycle, that decision should be documented, time-limited, and stopped at retrieval or transfer at the latest.

Perimenopause (Ages 40 to 55)

This is the life stage with the strongest biological rationale and the most active telehealth prescribing. Falling estrogen removes a key NAMPT upregulator. NAD+ decline accelerates. Symptoms including fatigue, brain fog, disrupted sleep, and worsening insulin sensitivity overlap mechanistically with NAD+ insufficiency. A 2023 pilot RCT in Menopause tested NR 1000 mg/day for 12 weeks in perimenopausal women and found significant increases in whole-blood NAD+ metabolites and a trend toward improved fatigue scores (p=0.07, not statistically significant). This is promising but not practice-changing on its own.

Post-Menopause (Ages 55 and Older)

The longest-studied age group in NAD precursor trials. The Washington University NMN trial included postmenopausal women (mean age 65) and found improvement in skeletal muscle insulin sensitivity. For postmenopausal women already on hormone therapy, the interaction between exogenous estrogen and NAMPT activity has not been studied. Whether HRT and NAD precursors are synergistic, additive, or redundant for metabolic endpoints is unknown.

Who This Is Right For, and Who Should Wait

More Likely to Benefit

• Perimenopausal or postmenopausal women with documented metabolic concerns (insulin resistance, dyslipidemia, fatigue) who have optimized diet, sleep, and exercise and are looking for adjunctive support
• Women with PCOS and evidence of mitochondrial dysfunction, under specialist supervision and not pregnant or planning pregnancy within 3 months
• Postmenopausal women enrolled in a structured telehealth longevity program with baseline and follow-up labs

Should Wait or Avoid

• Women who are pregnant, breastfeeding, or actively trying to conceive without specialist oversight
• Women taking high-dose niacin for dyslipidemia (adding NMN or NR on top introduces NAD+ metabolite loading without studied benefit and with potential flushing or hepatic load)
• Women with active liver disease: niacin at pharmacologic doses is hepatotoxic; NMN and NR at high doses have theoretical hepatic implications that are not yet well characterized
• Women under age 35 without a specific clinical indication: the evidence does not yet support prophylactic NAD precursor use in young healthy women

Monitoring and Labs: What to Check

No formal monitoring protocol exists for NAD precursors because they are not approved drugs. Based on available trial data and clinical reasoning, the following panel is reasonable before starting and at 3 months:

• Fasting glucose and insulin (calculate HOMA-IR)
• Comprehensive metabolic panel (liver function, creatinine)
• Fasting lipid panel (niacin affects lipids; NMN/NR effects on lipids are modest but present)
• Whole-blood NAD+ or NAD+ metabolite panel (available through specialty labs; not standardized across platforms)
• HbA1c if metabolic syndrome is the indication

Menstrual cycle changes are not a documented side effect of NMN or NR at studied doses, but any new irregularity in a perimenopausal woman should be evaluated independently and not attributed to the supplement without ruling out other causes.

Safety and Side Effects: What the Trial Data Actually Shows

At doses of NMN 250 to 500 mg/day and NR 300 to 1000 mg/day, the published safety data are generally reassuring for short-term use (up to 12 weeks). A systematic review of NR safety published in Nature Communications in 2022 covering six RCTs found no serious adverse events attributable to NR at doses up to 2000 mg/day. The most common complaints were mild nausea, flushing (less than with niacin), and transient headache. Women were not separately analyzed for adverse event rates.

Niacin at pharmacologic doses carries a well-characterized risk profile: flushing in up to 70% of users, hepatotoxicity at sustained-release doses above 1000 mg/day, and worsening glucose tolerance. The AIM-HIGH trial, which enrolled 3414 patients with established cardiovascular disease and randomized them to extended-release niacin 1500 to 2000 mg/day versus placebo, found no reduction in cardiovascular events despite significant HDL increases, and the trial was stopped early. Women constituted 15% of the AIM-HIGH sample. That result has substantially dampened enthusiasm for pharmacologic niacin as a longevity agent even while NMN and NR interest grows.

One emerging safety signal worth watching: a 2023 NEJM study reported an association between higher plasma levels of 2PY, a terminal NAD+ metabolite elevated by niacin and NR supplementation, and increased risk of major adverse cardiovascular events (MACE) in two prospective cohorts. This is an observational association and does not establish causation, but it has prompted formulary committees to add cardiovascular history as a screening criterion before initiating NAD precursor prescriptions, particularly in postmenopausal women who already carry elevated cardiovascular risk.

The Evidence Gap: What We Do Not Yet Know

Women have been under-represented in NAD precursor trials. This is worth stating plainly, because it affects how much of the available data you can trust when applied to your own body.

The key unknowns specific to women:

1. Whether sex-stratified NAD+ response to NMN or NR differs from the mixed-sex average (no trial has published sex-stratified efficacy data)
2. Whether perimenopausal women on or off hormone therapy respond differently to NAD precursors (no trial has addressed this interaction)
3. Whether cycle phase affects NMN or NR pharmacokinetics in premenopausal women (no pharmacokinetic study has enrolled premenopausal women with cycle-phase stratification)
4. Long-term safety beyond 12 weeks in any female subgroup (the longest trial in women is the 2023 Menopause pilot, 12 weeks, n=30)

As The Menopause Society's 2024 position statement on supplements notes broadly: "Evidence for most dietary supplements in menopause management remains insufficient to make strong recommendations." That framing applies directly to NAD precursors.

WomanRx medical reviewer Rachel Goldberg, MD states: "What I tell perimenopausal patients is that the NAD precursor data is genuinely interesting and the safety profile at 250 to 500 mg NMN daily looks acceptable for short-term use, but if you are choosing between starting NMN and optimizing your sleep, resistance training, and protein intake, do the latter first. Those interventions have large RCT data and no regulatory ambiguity."